Biodexa Pharmaceuticals Plc (NASDAQ:BDRX - Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 36,100 shares, a drop of 23.2% from the February 13th total of 47,000 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 830,300 shares, the short-interest ratio is currently 0.0 days.
Biodexa Pharmaceuticals Stock Performance
Shares of NASDAQ BDRX traded up $0.22 during mid-day trading on Wednesday, reaching $2.24. The company had a trading volume of 27,964,020 shares, compared to its average volume of 472,120. Biodexa Pharmaceuticals has a one year low of $1.84 and a one year high of $74.00. The company has a 50-day moving average price of $3.81.
Biodexa Pharmaceuticals Company Profile
(
Get Free Report)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Featured Stories
Before you consider Biodexa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodexa Pharmaceuticals wasn't on the list.
While Biodexa Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
